Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Other Non-Current Assets: 2017-2025

Historic Other Non-Current Assets for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $2.8 million.

  • Aclaris Therapeutics' Other Non-Current Assets fell 11.91% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 11.91%. This contributed to the annual value of $3.1 million for FY2024, which is 26.26% down from last year.
  • Aclaris Therapeutics' Other Non-Current Assets amounted to $2.8 million in Q3 2025, which was down 5.31% from $3.0 million recorded in Q2 2025.
  • Aclaris Therapeutics' Other Non-Current Assets' 5-year high stood at $4.2 million during Q4 2023, with a 5-year trough of $2.7 million in Q3 2023.
  • Its 3-year average for Other Non-Current Assets is $3.2 million, with a median of $3.2 million in 2025.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first surged by 52.20% in 2023, then declined by 26.26% in 2024.
  • Over the past 5 years, Aclaris Therapeutics' Other Non-Current Assets (Quarterly) stood at $3.6 million in 2021, then dropped by 23.13% to $2.7 million in 2022, then spiked by 52.20% to $4.2 million in 2023, then decreased by 26.26% to $3.1 million in 2024, then declined by 11.91% to $2.8 million in 2025.
  • Its Other Non-Current Assets was $2.8 million in Q3 2025, compared to $3.0 million in Q2 2025 and $3.2 million in Q1 2025.